123 related articles for article (PubMed ID: 36653078)
1. Protocol for the murine antibody-dependent cellular phagocytosis assay.
Stanganello E; Brkic M; Zenner S; Beulshausen I; Schmitt U; Vascotto F
Methods Cell Biol; 2023; 173():109-120. PubMed ID: 36653078
[TBL] [Abstract][Full Text] [Related]
2. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
3. Method for Measurement of Antibody-Dependent Cellular Phagocytosis.
Kamen L; Ordonia B; Myneni S; Chung S
Methods Mol Biol; 2022; 2313():305-312. PubMed ID: 34478147
[TBL] [Abstract][Full Text] [Related]
4. Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance.
Pinney JJ; Rivera-Escalera F; Chu CC; Whitehead HE; VanDerMeid KR; Nelson AM; Barbeau MC; Zent CS; Elliott MR
Blood; 2020 Oct; 136(18):2065-2079. PubMed ID: 32556153
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses.
Tay MZ; Wiehe K; Pollara J
Front Immunol; 2019; 10():332. PubMed ID: 30873178
[TBL] [Abstract][Full Text] [Related]
6. A novel method for determining antibody-dependent cellular phagocytosis.
Kamen L; Myneni S; Langsdorf C; Kho E; Ordonia B; Thakurta T; Zheng K; Song A; Chung S
J Immunol Methods; 2019 May; 468():55-60. PubMed ID: 30880262
[TBL] [Abstract][Full Text] [Related]
7. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies.
Liu C; Yu C; Yang Y; Huang J; Yu X; Duan M; Wang L; Wang J
Int Immunopharmacol; 2021 Nov; 100():108112. PubMed ID: 34521023
[TBL] [Abstract][Full Text] [Related]
9. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
10. Differential influence on antibody dependent cellular phagocytosis by different glycoforms on therapeutic Monoclonal antibodies.
Kuhns S; Shu J; Xiang C; Guzman R; Zhang Q; Bretzlaff W; Miscalichi N; Kalenian K; Joubert M
J Biotechnol; 2020 Jun; 317():5-15. PubMed ID: 32361021
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.
Shi Y; Fan X; Deng H; Brezski RJ; Rycyzyn M; Jordan RE; Strohl WR; Zou Q; Zhang N; An Z
J Immunol; 2015 May; 194(9):4379-86. PubMed ID: 25795760
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.
Kurdi AT; Glavey SV; Bezman NA; Jhatakia A; Guerriero JL; Manier S; Moschetta M; Mishima Y; Roccaro A; Detappe A; Liu CJ; Sacco A; Huynh D; Tai YT; Robbins MD; Azzi J; Ghobrial IM
Mol Cancer Ther; 2018 Jul; 17(7):1454-1463. PubMed ID: 29654064
[TBL] [Abstract][Full Text] [Related]
13. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
14. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.
Tipton TR; Roghanian A; Oldham RJ; Carter MJ; Cox KL; Mockridge CI; French RR; Dahal LN; Duriez PJ; Hargreaves PG; Cragg MS; Beers SA
Blood; 2015 Mar; 125(12):1901-9. PubMed ID: 25631769
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.
Su S; Zhao J; Xing Y; Zhang X; Liu J; Ouyang Q; Chen J; Su F; Liu Q; Song E
Cell; 2018 Oct; 175(2):442-457.e23. PubMed ID: 30290143
[TBL] [Abstract][Full Text] [Related]
16. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
VanDerMeid KR; Elliott MR; Baran AM; Barr PM; Chu CC; Zent CS
Cancer Immunol Res; 2018 Oct; 6(10):1150-1160. PubMed ID: 30089638
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis.
Naicker SD; Feerick CL; Lynch K; Swan D; McEllistrim C; Henderson R; Leonard NA; Treacy O; Natoni A; Rigalou A; Cabral J; Chiu C; Sasser K; Ritter T; O'Dwyer M; Ryan AE
Oncoimmunology; 2021 Jan; 10(1):1859263. PubMed ID: 33552684
[TBL] [Abstract][Full Text] [Related]
18. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.
Ashraf SQ; Umana P; Mössner E; Ntouroupi T; Brünker P; Schmidt C; Wilding JL; Mortensen NJ; Bodmer WF
Br J Cancer; 2009 Nov; 101(10):1758-68. PubMed ID: 19904275
[TBL] [Abstract][Full Text] [Related]
19. Macrophage N-glycan processing inhibits antibody-dependent cellular phagocytosis.
Díaz de León JSA; Aguilar I; Barb AW
Glycobiology; 2023 Dec; 33(12):1182-1192. PubMed ID: 37792857
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner.
Musich T; Li L; Liu L; Zolla-Pazner S; Robert-Guroff M; Gorny MK
J Virol; 2017 Apr; 91(8):. PubMed ID: 28122974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]